← Back to Search

Vacuum-Assisted Closure Device

Prevena Therapy for Spine Surgery

Phase 4
Recruiting
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-6 weeks following surgery
Awards & highlights

Summary

This trial is testing a special bandage that uses suction to help wounds heal faster in patients having spine surgery. The goal is to see if it can prevent infections and other problems better than regular bandages. The study will also find out which patients benefit the most from using this device.

Who is the study for?
This trial is for adults over 18 who are having spine surgery and need a plastic surgeon to close the wound. They must have a risk score of 80 or above, indicating they're at higher risk for complications. Pregnant individuals, those with low-risk scores, or with conditions that could affect study results or compliance can't participate.
What is being tested?
The study is testing Prevena Vacuum-Assisted Closure devices on patients undergoing spine surgery. It's designed to see if this device helps in healing surgical wounds better than usual methods.
What are the potential side effects?
While specific side effects aren't listed here, vacuum-assisted closure devices like Prevena may cause skin irritation, discomfort at the application site, or allergic reactions to adhesive materials used.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-6 weeks following surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-6 weeks following surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Seroma
Communicable Diseases
Frequency of Wound dehiscence
Secondary study objectives
Frequency of readmission
Frequency of skin necrosis

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Group 2 (Prevena)Active Control2 Interventions
Prospective group of patients receiving spine surgery who will have Prevena applied to incision area.
Group II: Group 1 (control)Placebo Group1 Intervention
Retrospective control of patients who did not use Prevena following spine surgery.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The Prevena Vacuum-Assisted Closure (VAC) device operates by applying negative pressure to surgical incisions, which helps to remove exudate and infectious materials from the wound site. This negative pressure promotes increased blood flow, reduces edema, and draws the edges of the wound together, thereby accelerating the healing process. For surgery patients, this is particularly important as it not only speeds up recovery but also significantly reduces the risk of postoperative infections, which can lead to complications and prolonged hospital stays.
The clinical efficacy and cost effectiveness of the vacuum-assisted closure technique in the management of acute and chronic wounds: a randomized controlled trial.

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,625 Previous Clinical Trials
937,004 Total Patients Enrolled
16 Trials studying Surgery
787 Patients Enrolled for Surgery
3MIndustry Sponsor
158 Previous Clinical Trials
31,199 Total Patients Enrolled
1 Trials studying Surgery
247 Patients Enrolled for Surgery

Media Library

Prevena Spine (Vacuum-Assisted Closure Device) Clinical Trial Eligibility Overview. Trial Name: NCT05555355 — Phase 4
Surgery Research Study Groups: Group 2 (Prevena), Group 1 (control)
Surgery Clinical Trial 2023: Prevena Spine Highlights & Side Effects. Trial Name: NCT05555355 — Phase 4
Prevena Spine (Vacuum-Assisted Closure Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05555355 — Phase 4
~104 spots leftby Sep 2025